vs
Side-by-side financial comparison of AMERICAN AXLE & MANUFACTURING HOLDINGS INC (AXL) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.4B, roughly 1.7× AMERICAN AXLE & MANUFACTURING HOLDINGS INC). Zoetis runs the higher net margin — 25.3% vs -5.4%, a 30.7% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs 0.2%). Zoetis produced more free cash flow last quarter ($732.0M vs $54.7M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -7.2%).
American Axle & Manufacturing, Inc. (AAM), headquartered in Detroit, Michigan, is an American manufacturer of automobile driveline and drivetrain components and systems.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
AXL vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.4B |
| Net Profit | $-75.3M | $603.0M |
| Gross Margin | 10.2% | 70.2% |
| Operating Margin | -2.4% | 31.9% |
| Net Margin | -5.4% | 25.3% |
| Revenue YoY | 0.2% | 3.0% |
| Net Profit YoY | -449.6% | 3.8% |
| EPS (diluted) | $-0.62 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.5B | $2.4B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.5B | $2.4B | ||
| Q2 24 | $1.6B | $2.4B | ||
| Q1 24 | $1.6B | $2.2B |
| Q4 25 | $-75.3M | $603.0M | ||
| Q3 25 | $9.2M | $721.0M | ||
| Q2 25 | $39.3M | $718.0M | ||
| Q1 25 | $7.1M | $631.0M | ||
| Q4 24 | $-13.7M | $581.0M | ||
| Q3 24 | $10.0M | $682.0M | ||
| Q2 24 | $18.2M | $624.0M | ||
| Q1 24 | $20.5M | $599.0M |
| Q4 25 | 10.2% | 70.2% | ||
| Q3 25 | 12.6% | 71.5% | ||
| Q2 25 | 13.1% | 73.6% | ||
| Q1 25 | 12.3% | 72.0% | ||
| Q4 24 | 11.2% | 69.5% | ||
| Q3 24 | 11.4% | 70.6% | ||
| Q2 24 | 13.3% | 71.7% | ||
| Q1 24 | 12.4% | 70.6% |
| Q4 25 | -2.4% | 31.9% | ||
| Q3 25 | 3.2% | 37.0% | ||
| Q2 25 | 3.6% | 36.7% | ||
| Q1 25 | 3.0% | 36.5% | ||
| Q4 24 | 2.6% | 31.6% | ||
| Q3 24 | 2.8% | 36.6% | ||
| Q2 24 | 5.3% | 33.0% | ||
| Q1 24 | 4.8% | 34.1% |
| Q4 25 | -5.4% | 25.3% | ||
| Q3 25 | 0.6% | 30.0% | ||
| Q2 25 | 2.6% | 29.2% | ||
| Q1 25 | 0.5% | 28.4% | ||
| Q4 24 | -1.0% | 25.1% | ||
| Q3 24 | 0.7% | 28.6% | ||
| Q2 24 | 1.1% | 26.4% | ||
| Q1 24 | 1.3% | 27.4% |
| Q4 25 | $-0.62 | $1.37 | ||
| Q3 25 | $0.07 | $1.63 | ||
| Q2 25 | $0.32 | $1.61 | ||
| Q1 25 | $0.06 | $1.41 | ||
| Q4 24 | $-0.11 | $1.29 | ||
| Q3 24 | $0.08 | $1.50 | ||
| Q2 24 | $0.15 | $1.37 | ||
| Q1 24 | $0.17 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $708.9M | — |
| Total DebtLower is stronger | $4.0B | — |
| Stockholders' EquityBook value | $640.0M | $3.3B |
| Total Assets | $6.7B | $15.5B |
| Debt / EquityLower = less leverage | 6.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $708.9M | — | ||
| Q3 25 | $714.1M | $2.1B | ||
| Q2 25 | $586.5M | $1.4B | ||
| Q1 25 | $549.2M | $1.7B | ||
| Q4 24 | $552.9M | $2.0B | ||
| Q3 24 | $542.5M | $1.7B | ||
| Q2 24 | $519.9M | $1.6B | ||
| Q1 24 | $469.8M | $2.0B |
| Q4 25 | $4.0B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $640.0M | $3.3B | ||
| Q3 25 | $718.4M | $5.4B | ||
| Q2 25 | $673.0M | $5.0B | ||
| Q1 25 | $596.3M | $4.7B | ||
| Q4 24 | $562.8M | $4.8B | ||
| Q3 24 | $616.3M | $5.2B | ||
| Q2 24 | $609.6M | $5.0B | ||
| Q1 24 | $621.4M | $5.1B |
| Q4 25 | $6.7B | $15.5B | ||
| Q3 25 | $5.3B | $15.2B | ||
| Q2 25 | $5.3B | $14.5B | ||
| Q1 25 | $5.1B | $14.1B | ||
| Q4 24 | $5.1B | $14.2B | ||
| Q3 24 | $5.3B | $14.4B | ||
| Q2 24 | $5.3B | $14.2B | ||
| Q1 24 | $5.4B | $14.3B |
| Q4 25 | 6.31× | — | ||
| Q3 25 | 3.61× | — | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 4.38× | — | ||
| Q4 24 | 4.58× | — | ||
| Q3 24 | 4.28× | — | ||
| Q2 24 | 4.42× | — | ||
| Q1 24 | 4.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.5M | $893.0M |
| Free Cash FlowOCF − Capex | $54.7M | $732.0M |
| FCF MarginFCF / Revenue | 4.0% | 30.7% |
| Capex IntensityCapex / Revenue | 4.8% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $155.1M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.5M | $893.0M | ||
| Q3 25 | $143.3M | $938.0M | ||
| Q2 25 | $91.9M | $486.0M | ||
| Q1 25 | $55.9M | $587.0M | ||
| Q4 24 | $151.2M | $905.0M | ||
| Q3 24 | $143.6M | $951.0M | ||
| Q2 24 | $142.8M | $502.0M | ||
| Q1 24 | $17.8M | $595.0M |
| Q4 25 | $54.7M | $732.0M | ||
| Q3 25 | $79.2M | $805.0M | ||
| Q2 25 | $34.6M | $308.0M | ||
| Q1 25 | $-13.4M | $438.0M | ||
| Q4 24 | $73.2M | $689.0M | ||
| Q3 24 | $70.4M | $784.0M | ||
| Q2 24 | $94.0M | $370.0M | ||
| Q1 24 | $-30.2M | $455.0M |
| Q4 25 | 4.0% | 30.7% | ||
| Q3 25 | 5.3% | 33.5% | ||
| Q2 25 | 2.3% | 12.5% | ||
| Q1 25 | -0.9% | 19.7% | ||
| Q4 24 | 5.3% | 29.7% | ||
| Q3 24 | 4.7% | 32.8% | ||
| Q2 24 | 5.8% | 15.7% | ||
| Q1 24 | -1.9% | 20.8% |
| Q4 25 | 4.8% | 6.7% | ||
| Q3 25 | 4.3% | 5.5% | ||
| Q2 25 | 3.7% | 7.2% | ||
| Q1 25 | 4.9% | 6.7% | ||
| Q4 24 | 5.6% | 9.3% | ||
| Q3 24 | 4.9% | 7.0% | ||
| Q2 24 | 3.0% | 5.6% | ||
| Q1 24 | 3.0% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 15.58× | 1.30× | ||
| Q2 25 | 2.34× | 0.68× | ||
| Q1 25 | 7.87× | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 14.36× | 1.39× | ||
| Q2 24 | 7.85× | 0.80× | ||
| Q1 24 | 0.87× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXL
| Driveline | $748.4M | 54% |
| Other | $345.7M | 25% |
| Metal Forming | $289.8M | 21% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
